FBR & Co restated their outperform rating on shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) in a research report sent to investors on Wednesday. FBR & Co currently has a $36.00 target price on the stock.
Several other research analysts have also recently commented on RDHL. Zacks Investment Research cut shares of RedHill Biopharma from a buy rating to a hold rating in a report on Wednesday, July 6th. HC Wainwright set a $33.00 price target on shares of RedHill Biopharma and gave the stock a buy rating in a report on Friday, October 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of Buy and an average target price of $26.20.
RedHill Biopharma (NASDAQ:RDHL) opened at 13.53 on Wednesday. RedHill Biopharma has a one year low of $8.10 and a one year high of $16.54. The stock’s market cap is $172.29 million. The company’s 50 day moving average is $14.53 and its 200 day moving average is $12.84.
RedHill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.52. On average, equities research analysts expect that RedHill Biopharma will post ($2.06) EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. bought a new position in shares of RedHill Biopharma during the second quarter valued at about $142,000. Van ECK Associates Corp boosted its position in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the last quarter. Ingalls & Snyder LLC bought a new position in shares of RedHill Biopharma during the second quarter valued at about $451,000. Finally, Royal Bank of Canada boosted its position in shares of RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the last quarter. Institutional investors and hedge funds own 15.30% of the company’s stock.
About RedHill Biopharma
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.